Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jun 13, 2021
Open Peer Review Period: Apr 8, 2021 - Jun 3, 2021
Date Accepted: Sep 3, 2021
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Supportive Text Messaging versus Supportive E-mail Messaging for Patients with Major Depressive Disorder: Randomized Hybrid Type II Effectiveness-Implementation Trial Protocol
ABSTRACT
Background:
Major Depressive Disorder (MDD) accounts for 40ยท5% of disability-adjusted life years caused by mental and substance use disorders. Barriers such as stigma, financial and physical access to care have been reported, highlighting need for innovative, accessible and cost-effective psychological interventions. The effectiveness of supportive text messaging in alleviating depression symptoms has been proven in clinical trials, but this approach can only those with active cell phones. Consequently, this study seeks to evaluate the feasibility, comparative effectiveness, and user satisfaction of daily supportive daily e-mail messaging as an effective strategy compared to daily supportive text messaging, as part of treatment of patients with MDD.
Objective:
The Supportive Text versus Email Messaging (STEM) trial aims to evaluate comparatively the implementation and impact of two implementation strategies (text messaging and email messaging) for delivering supportive messages to patients with MDD.
Methods:
This trial will be carried out using a type II implementation-effectiveness hybrid trial. This design evaluates the effectiveness of an implementation strategy or intervention, while also evaluating the implementation context associated with the intervention. In this innovative pilot trial, patients with MDD receiving usual care will be randomized to receive either daily supportive email messaging or daily supportive text messaging of the same content for six months. The Patient Health Questionnaire (PHQ)-9 scale, the Generalized Anxiety Disorder (GAD)-7 scale and the WHO (Five) Well-Being Index will be used to evaluate the effectiveness of both strategies. Implementation evaluation will be guided by the Reach-Effectiveness-Adoption-Implementation-Maintenance (RE_AIM) framework, as well as the Consolidated Framework for Implementation Research (CFIR). All outcome measures will be analyzed using descriptive and inferential statistics. Qualitative data will be analyzed using thematic analysis.
Results:
Data collection for this trial began in April 2021. We expect the study results to be available within 18 months of study commencement. The study results will shed light on the feasibility, acceptability and effectiveness of using automated emails as a strategy for delivering supportive messages to patients with MDD, in comparison to text messaging.
Conclusions:
The outcome of this trial will have translational impact on routine patient care, access to mental health as well as potentially support mental health policy decision making for healthcare resource allocation. Clinical Trial: ClinicalTrials.gov Identifier: NCT04638231
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.